Source 3 Registry studies use of Edwards SAPIEN 3 valve for patients with aortic stenosis.

The SOURCE 3 Registry, a monitored and adjudicated prospective registry, is studying use of the low-profile Edwards SAPIEN 3 valve in a real-world commercial setting, treating patients with severe, symptomatic aortic stenosis. Patients treated via the transfemoral access route had a high survival rate of 98.1 percent at 30 days. Additionally, the study found a low stroke rate of 1.2 percent in transfemoral patients.

Data from the SOURCE 3 Registry documented the outcomes of 1,947 patients treated at 80 centers in Europe performing transcatheter aortic valve replacement (TAVR). Patients were enrolled in 10 countries between July 2014 and October 2015 and will be followed for five years. This represents the first large, multi-center report of SAPIEN 3 valve patient outcomes in a commercial setting, as well as the largest dataset of patients who were treated using conscious sedation with a singular valve platform (1,018 patients). Patients treated under conscious sedation are awake during the procedure and do not receive general anesthesia. The Edwards SAPIEN 3 valve has been available in Europe since 2014. The Edwards SAPIEN family of valves are the most studied transcatheter heart valves in history and have been used in the treatment of more than 150,000 patients globally.